Developing antibodies to combat antibiotic-resistant bacterial infections
Official title: Multidimensional development of high-affinity anti-glycan antibodies to fight deadly bacterial infections
Funded at Scripps Research Institute, the · NIH-11082422 · Data updated 2026-11-12
This study is working on new ways to help your immune system recognize and fight off tough bacteria by using special structures on their surface, which could lead to better vaccines and treatments for infections that don't respond to regular antibiotics.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scripps Research Institute, the NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | May 9, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $1,961,391 |
| NIH project number | 5P01AI172525-03 |
| Project ID | NIH-11082422 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from severe bacterial infections, especially those caused by antibiotic-resistant strains.
✕Less likely to help
Patients with infections caused by non-bacterial pathogens or those who do not respond to immunotherapy may not benefit from this research.
What this research studies
This research focuses on creating immunotherapies that target the surface structures of bacteria, known as glycans, which are crucial for their survival and virulence. By using advanced chemistry techniques, the research team will construct artificial platforms to display these glycans, making them recognizable to the immune system. The project aims to analyze immune responses to these glycans to develop effective vaccines and antibodies that can be used against antibiotic-resistant bacteria. The collaboration of experts in various fields will enhance the understanding of how to effectively combat these infections.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively fight deadly bacterial infections, particularly those resistant to current antibiotics.
How similar studies have gone: Previous research has shown promising results in developing high-affinity antibodies against bacterial glycans, indicating potential for success in this novel approach.
Where this research is happening
-
Scripps Research Institute, the
La Jolla, United States Active
Researchers
- Principal investigator: Teyton, Luc — Scripps Research Institute, the
- Study coordinator: Teyton, Luc
Related research
Other NIH-funded projects on the same topics.
-
Host-Directed Orynotide for MDR Gram-Negative Infections
A new drug candidate called Orynotide MTD12813 is being developed to treat serious drug-resistant infections caused by bacteria like Acinetobacter and Enterobacteriaceae.
-
Genomic-informed, low-cost, portable test to rapidly identify drug-resistant bacterial infections
A portable, affordable test called BADLOCK could quickly identify bacteria and resistance genes from blood samples to help treat drug-resistant infections.
-
Novel BMX antibiotics for tough Gram-negative infections
A new class of BMX antibiotics is being developed to fight hard-to-treat Gram-negative infections like Acinetobacter baumannii in patients.
-
Center to speed up antibacterial drugs for hard-to-treat infections
A national center at Hackensack University Medical Center aims to speed up the development of new antibiotics to fight high-threat, drug-resistant bacterial infections.
-
Center accelerating antibiotic development for high-threat bacterial infections
A research center in academia–industry collaboration is speeding up the development of new antibiotics to fight highly resistant bacteria so patients have better treatment options.
-
PACC1 in the body’s defense against bacterial infections and sepsis
A study exploring how a protein called PACC1 helps immune cells fight bacteria and prevent sepsis, with potential benefits for people at risk of severe infections.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.